Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada

View Full Paper
Ask AI
Bookmark
Share

Authors

CZCraig ZimmermanTris Pharma (United States)

Discussion

Loading...

Member takes

Overview

The analysis reveals substantial incidence and prevalence of essential thrombocythemia patients eligible for cytoreductive therapies in US health plans, indicating a need for policy focus.

Key Points

  • This analysis estimates the incidence and prevalence of essential thrombocythemia patients in the U.S. and Canada eligible for cytoreductive therapies.
  • Systematically assessed literature for epidemiological data on essential thrombocythemia (ET) prevalence and incidence.
  • Utilized membership data from the eight largest U.S. commercial health plans for modeling analyses.
  • Estimated treatment-eligible populations based on NCCN guidelines and IPSET-thrombosis risk stratification.
  • Identified approximately 426 incident and 16,915 prevalent ET patients in U.S. health plans.
  • Estimated 281 incident and 11,164 prevalent ET patients in Canada.
  • Cytoreductive therapy usage was about 72.5%, with averages of 128 incident and 5,101 prevalent patients in U.S. health plans.

Cite This Study

Craig Zimmerman (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc3bhttps://doi.org/10.1182/blood-2025-8199
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data2025
  2. 2Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans2025 · 1 citations
  3. 3Essential thrombocythaemia: A contemporary approach with new drugs on the horizon2024 · 7 citations
  4. 4Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.2025
  5. 5Is essential thrombocytosis associated with worse outcomes in patients with stroke? Results from 2016-2020 National Inpatient Sample study.2024